louisiana semaglutide stomach paralysis law office Ozempic Lawsuit Lawsuit Against Ozempic Manufacturers Claims

In the SURMOUNT-1 trial, patients taking Zepbound achieved substantial weight reduction compared to placebo, with many participants losing 15% or more of their baseline body weight

1764 T2D has been shown to be associated with increased risk for hepatic, 1765 bladder, 1766 pancreatic, 1767,1768 and colorectal cancers

Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which help lower blood sugar levels by increasing insulin production, reducing glucagon secretion, and slowing digestion

Because type 2 diabetes requires in-depth care including glucose monitoring and regular testing, Klinic focuses on weight management

Now add a GLP-1 to that landscape, and the conversation around GLP-1s and perimenopause becomes much more important

Available from: Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresr KM, Gomes FA, et al